March 24, 2022 5:23pm

Standing tall oscillating between continuing gains and few losses

Pre-open indications: 10 Hits and 3 MISS

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

The metrics say it all … just the facts

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +349.11 points (+1.02%); the S&P closed UP +63.92 points (+1.43%) while the Nasdaq closed UP +269.24 points (+1.93%)

 

Henry’omics:

U.S. indexes rose Thursday as investors continued to weigh a number of risks, the Fed’s “wishy-washy” inflation flight and Russia’s war on Ukraine.

Economic data Docket: Jobless claims last week fell to 187,000 from 215,000 the previous week. <Labor Department>

·         That was the lowest level for initial claims in over 52 years, going back to September 1969. Economists had forecast 210,000 new claims. That's good news for workers, but not for companies that are facing a labor shortage.

·         the S&P's Purchasing Manufacturers Index came out Thursday showing an expansion of the U.S. private sector. It showed demand strengthening and supply issues softening. The PMI composite in March came in at 58.5, an eight-month high and an increase from 55.9 in February.

·         Orders for durable goods fell 2.2% in February. The decline was worse than estimates for a 0.5% drop and a slowdown from the 1.6% increases the previous month. <IBD>

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Thursday opened negative at 15 up/17 downs, 3 flats, flipped positive at the mid-day at 25/9 and 1 flat, ending with a negative close of 28/6 and 1 flat;

 

Pre-open Indications: 10 Hits < Biostage (BSTG -$0.0); BUY: Sage Therapeutics (SAGE +$0.04), Precigen (PGEN +$0.03), MiMedx (MDXG +$0.06), Beam Therapeutics (BEAM +$1.90), Cellectis SA (CLLS +$0.30), CRISPR Therapeutics (CRSP +$0.83), Intellia Therapeutics (NTLA +$1.77), Sangamo Therapeutics (SGMO +$0.16), Vericel (VCEL +$1.26)> 3 Miss < Global Blood Therapeutics (GBT +$1.29), AxoGen (AXGN -$0.01), BioLife Solutions (BLFS -$0.15)>

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  … (FIXX, CRBU and BLCM) added with 31 to date

 

Key Metrics:

  • Thursday - Sector volume was LOW with 4 of the 28-upside having higher than the 3-month average volume with LOW volume of 1 of 6-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB was up +1.39% and the XBI was up +2.13%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -1.90 points or -8.06% at 21.67

 

Jumping with share pricing momentum (10 of 28):

  • Regenxbio (RGNX +$1.90 after Wednesday’s +$2.08, Wednesday’s +$0.13 and Tuesday’s +$0.69),
  • Beam Therapeutics (BEAM -$4.90 after Tuesday’s +$2.55 and Monday’s -$3.98),
  • Intellia Therapeutics (NTLA +$1.77 after Wednesday’s -$3.30, Tuesday’s +$3.48 and Monday’s -$2.37),
  • Fate Therapeutics (FATE +$1.74 after Wednesday’s -$0.96),
  • Alnylam Pharmaceuticals (ALNY+$1.35 after Wednesday’s -$1.48, Tuesday’s +$1.40 and Monday’s -$2.82),
  • Global Blood Therapeutics (GBT +$1.29),
  • Vericel (VCEL +$1.26 after Wednesday’s +$0.77, Tuesday’s +$1.07 and Monday’s -$1.62),
  • Ionis Pharmaceuticals (IONS +$1.25 after Wednesday’s -$0.61, Tuesday’s +$1.36 and Monday’s -$0.33),
  • CRISPR Therapeutics (CRSP +$0.83 after Wednesday’s -$3.93, Tuesday’s +$1.84 after Monday’s -$2.23),
  • Editas Medicine (EDIT +$0.74),

Hammered in today’s market (6 of 6):

  • BioLife Solutions (BLFS -$0.15 after Wednesday’s -$1.00 and Tuesday’s -$1.64),
  • Caribou Biosciences (CRBU -$0.09),
  • Verastem (VSTM -$0.05),
  • Applied Genetic Technologies (AGTC -$0.04),
  • Homology Medicine (FIXX -$0.04),
  • AxoGen (AXGN -$0.01),

Closing Flat:

  • Biostage (BSTG)

 

March, Q1/2022:

  • Thursday closed positive with 28 incliners, 6 decliners and 1 flat

 

The BOTTOM LINE: The cell and gene therapy sector piggybacked on the Nasdaq even as economic reports showed a tighter-than-expected job market and an expansion in the private sector.

Leading today’s session and coming back from the downside was Beam Therapeutics (BEAM) while the biggest loser, BioLife Solutions (BLFS) dived after a positive showing on Wednesday.

Cell and gene stocks gained after falling Wednesday to give back some gains after rising a day (Tuesday), as investors after feeling the upside and battling the sell options and risks of dramatic move to the upside after a Monday’s crash.

I am still maintaining,” Caution is in order.”

What and which go up, also slip down; it’s sector physiology as risks go both ways.

Remember the adage, “It takes two to make a market"; that’s sellers and buyers.

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Q4 and end-of-year earnings are still “gamy” than even I thought – two (2) this week: FIXX and CRBU.

Earnings’ reporting coming:

·         Brainstorm Cell Therapeutics (BCLI), Monday, 3/28

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.